Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Misoprostol versus hypotensive anesthesia for blood loss control during abdominal myomectomy
IRCT20220930056059N1Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of misoprostol and labetalol in Fibromyoma (LM) (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoint: Control of amount of bleeding. Started Nov 2022; status: completed.
02
Drugs
misoprostollabetalol
03
Conditions
Fibromyoma (LM)
Beyond the preview
Go deeper on IRCT20220930056059N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220930056059N1.